Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

Company profile
Ticker
ATRS
Exchange
Website
CEO
Robert Apple
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...
Former names
ANTARES PHARMA INC, ANTARES PHARMA INC, ANTARES PHARMA INC /MN/, MEDI JECT CORP /MN/
SEC CIK
Corporate docs
IRS number
411350192
ATRS stock data
Calendar
10 May 22
9 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.72M | 61.72M | 61.72M | 61.72M | 61.72M | 61.72M |
Cash burn (monthly) | 1.4M | (no burn) | 1.05M | (no burn) | 1.63M | (no burn) |
Cash used (since last report) | 6.02M | n/a | 4.5M | n/a | 7M | n/a |
Cash remaining | 55.69M | n/a | 57.21M | n/a | 54.71M | n/a |
Runway (months of cash) | 39.8 | n/a | 54.7 | n/a | 33.6 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 May 22 | Greenleaf Peter | Common Stock | Sale back to company | Dispose D | No | No | 5.6 | 49,425 | 276.78K | 0 |
24 May 22 | Greenleaf Peter | Common Stock | Sale back to company | Dispose D | No | No | 5.6 | 30,220 | 169.23K | 0 |
24 May 22 | Greenleaf Peter | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.42 | 48,542 | 214.56K | 0 |
24 May 22 | Greenleaf Peter | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.73 | 58,246 | 159.01K | 0 |
24 May 22 | Greenleaf Peter | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.92 | 46,729 | 136.45K | 0 |
24 May 22 | Greenleaf Peter | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.11 | 20,000 | 62.2K | 0 |
24 May 22 | Powell Fred M | Common Stock | Sale back to company | Dispose D | No | No | 5.6 | 124,234 | 695.71K | 0 |
24 May 22 | Powell Fred M | Common Stock | Sale back to company | Dispose D | No | No | 5.6 | 204,022 | 1.14M | 0 |
24 May 22 | Powell Fred M | Common Stock | Sale back to company | Dispose D | No | No | 5.6 | 587,014 | 3.29M | 0 |
24 May 22 | Powell Fred M | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.42 | 163,963 | 724.72K | 0 |
Institutional ownership, Q1 2022
53.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 25 |
Closed positions | 12 |
Increased positions | 56 |
Reduced positions | 57 |
13F shares | Current |
---|---|
Total value | 375.15M |
Total shares | 91.58M |
Total puts | 24.8K |
Total calls | 316.9K |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 11.95M | $49.01M |
Rubric Capital Management | 10.9M | $44.69M |
Vanguard | 8.64M | $35.44M |
Sargent Investment | 3.66M | $15.02M |
Amundi | 3.45M | $13.95M |
STT State Street | 3.45M | $14.14M |
Stonepine Capital Management | 3.13M | $12.83M |
Russell Investments | 3.05M | $12.49M |
Geode Capital Management | 3M | $12.3M |
First Wilshire Securities Management | 2.8M | $11.48M |
Financial report summary
?Risks
- We may not complete the pending transaction with Halozyme within the time frame we anticipate or at all, which could have an adverse effect on our business, financial results and/or operations.
- The pendency of the transaction with Halozyme could adversely affect, or disrupt, our business, financial results and/or operations.
- While the Merger Agreement is in effect, we are subject to restrictions on our business activities.
- In certain instances, the Merger Agreement requires us to pay a termination fee to Halozyme, which could require us to use available cash that would have otherwise been available for general corporate purposes.
- We have incurred, and will continue to incur, direct and indirect costs as a result of the pending transaction with Halozyme.
Management Discussion
- Net revenue from product sales for the three months ended March 31, 2022 increased 10.2% over the same period in the prior year primarily driven by higher shipments of sumatriptan, epinephrine and teriparatide auto injectors to Teva and an increase in XYOSTED® proprietary product sales. The overall increase was partially offset by a reduction in OTREXUP® proprietary sales due to the sale of the OTREXUP® product line to Otter in December 2021.
- Sales of our proprietary products XYOSTED® and NOCDURNA® (and OTREXUP® during the three months ended March 31, 2021) are presented net of estimated product returns and sales allowances. FDA approval was granted on March 28, 2022 to commercialize TLANDO® with no sales transacted in the three months ended March 31, 2022 prior to timing of the approval. The decreases in proprietary product sales of 7.8% for the three months ended March 31, 2022 was primarily attributable to a reduction in OTREXUP® proprietary sales due to the sale of the OTREXUP® product line to Otter in December 2021 which is now commercialized by Otter, partially offset by continued growth in prescriptions and sales of XYOSTED® and NOCDURNA®.
- We also manufacture and sell devices, components and fully assembled and packaged product to our partners. Partnered product sales increased 42.5% for the three months ended March 31, 2022 primarily due to higher shipments of sumatriptan, epinephrine and teriparatide auto injectors to Teva.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absent, acquisition, Additionally, affirmative, affirming, annum, Antitrust, appraisal, Assertio, assumption, attention, bankruptcy, bear, benchmark, beneficially, Berry, book, candidate, casualty, certificate, cessation, CG, challenging, Circuit, clearance, condemnation, consent, constant, consummated, consummation, contend, covenant, create, curtail, customary, deadline, decide, defense, deficit, Delaware, Denise, deny, deposit, desire, devote, DGCL, difficult, direct, directed, directly, disorder, diversion, diverted, drawn, Eastern, EBITDA, economy, eliminated, elimination, engineering, enjoin, environment, event, exacerbated, exceed, expansion, extinguished, fact, failure, Fast, fewer, fluidity, gain, greater, Group, guaranteed, guarantor, Halozyme, harm, highest, hiring, hold, hope, HSR, hybrid, identical, iii, immunology, impossible, incurrence, independent, indirect, injunctive, installment, intent, interaction, intercompany, irrevocably, Joe, Jordan, Joseph, Lawrence, ligation, longer, macroeconomic, Matthew, member, merge, merger, minimum, modify, month, motivate, negative, negatively, notified, Ochoa, offer, omission, ordinary, organizational, Otter, par, passed, penalty, pendency, Pennsylvania, perfected, permitted, pivotal, pledge, practice, prefilled, premium, prepay, prime, proceeding, progressing, proper, properly, prospective, purportedly, qualified, rare, recover, recruit, Redfield, reinvestment, relationship, relief, repaid, repurchase, reputation, rescission, rescissory, retention, revise, Richard, Rule, ruled, sample, SEC, settlement, Shiva, slight, software, Southern, statutory, Stein, strictly, subsidiary, Supreme, surviving, syringe, team, tender, tendered, terminated, terminating, termination, thereof, thereunder, tied, timeframe, Track, trademark, TRT, turn, Undue, unused, Vai, validly, variety, vendor, viability, voluntarily, waiting, waiver, Wilson, withdrawn, withholding, York
Removed:
accelerated, accurate, allocation, amortizing, Arab, Arabia, ASC, Bone, capability, collaborating, commercializing, comprised, confirmatory, conform, defend, executing, finance, fluctuate, fluctuation, Gestation, guidance, heading, inaccuracy, inaccurate, incremental, interpret, leave, Neonatal, office, opinion, Optimizing, phased, PROLONG, promote, promotion, prove, publicly, pursue, reach, recently, reclassified, recommend, released, Reproductive, Role, Saudi, sheet, structured, taxable, temporary, Topic, unanticipated, unmet, Urologic, utilization, varying, vigorously, virtually, voted, withdrawal
Financial reports
Current reports
8-K
Entry into a Material Definitive Agreement
24 May 22
8-K
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
13 Apr 22
8-K
Regulation FD Disclosure
7 Mar 22
8-K
Antares Pharma Reports Fourth Quarter and Full-year
3 Mar 22
8-K/A
Regulation FD Disclosure
12 Jan 22
8-K
Regulation FD Disclosure
11 Jan 22
8-K
Entry into a Material Definitive Agreement
16 Dec 21
8-K
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
4 Nov 21
8-K
Entry into a Material Definitive Agreement
1 Nov 21
8-K
Antares Pharma Announces Appointment of Carmen Volkart to Its Board of Directors
28 Oct 21
Registration and prospectus
15-12B
Securities registration termination
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 22
Other
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
Ownership
4
ANTARES PHARMA / ROBERT P ROCHE JR ownership change
26 May 22
4
ANTARES PHARMA / ANTON GUETH ownership change
26 May 22
4
ANTARES PHARMA / Peter C Richardson ownership change
26 May 22
4
ANTARES PHARMA / Karen L. Smith ownership change
26 May 22
4
ANTARES PHARMA / LEONARD S JACOB ownership change
26 May 22
4
ANTARES PHARMA / PETER J GRAHAM ownership change
26 May 22
4
ANTARES PHARMA / THOMAS J GARRITY ownership change
26 May 22
4
ANTARES PHARMA / Fred M Powell ownership change
26 May 22
4
ANTARES PHARMA / ROBERT F APPLE ownership change
26 May 22
4
ANTARES PHARMA / Carmen B Volkart ownership change
26 May 22
Patents
Utility
Multiple Dosage Injector with Rotating Screw Dosage System
30 Jun 22
A dispensing mechanism for delivering a dosage of medicament including a housing having a proximal-distal axis; a plunger rod having a screw thread and configured to advance along the proximal-distal axis relative to the housing; a user-operable push button moveable along the proximal-distal axis relative to the housing; a twist driver threadably engaged with the push button such that movement of the push button towards the distal end of the housing causes rotation of the twist driver about the proximal-distal axis; and a driver engaged with the twist driver such that rotation of the twist driver causes rotation of the driver, the driver also engaged with a portion of the plunger rod such that rotation of the driver causes rotation of the plunger rod, advancing the plunger rod along the proximal-distal axis relative to the housing.
Utility
Hematocrit Modulation Through Needle Assisted Jet Injection of Testosterone
28 Apr 22
The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted injection device.
Utility
Multiple dosage injector with rotating screw dosage system
5 Apr 22
A dispensing mechanism for delivering a dosage of medicament including a housing having a proximal-distal axis; a plunger rod having a screw thread and configured to advance along the proximal-distal axis relative to the housing; a user-operable push button moveable along the proximal-distal axis relative to the housing; a twist driver threadably engaged with the push button such that movement of the push button towards the distal end of the housing causes rotation of the twist driver about the proximal-distal axis; and a driver engaged with the twist driver such that rotation of the twist driver causes rotation of the driver, the driver also engaged with a portion of the plunger rod such that rotation of the driver causes rotation of the plunger rod, advancing the plunger rod along the proximal-distal axis relative to the housing.
Utility
Aqueous Pharmaceutical Formulation of Hydrocortisone Sodium Phosphate and Monothioglycerol
31 Mar 22
Aqueous hydrocortisone sodium phosphate and monothioglycerol formulations are disclosed.
Utility
Testosterone Ester Triglyceride Formulations
17 Mar 22
Testosterone ester triglyceride formulations, optionally further including adducts.
Transcripts
2021 Q4
Earnings call transcript
3 Mar 22
2021 Q3
Earnings call transcript
4 Nov 21
2021 Q2
Earnings call transcript
5 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
5 May 20
2019 Q4
Earnings call transcript
3 Mar 20
2019 Q3
Earnings call transcript
5 Nov 19
Reddit threads
Daily Discussion Thread - May 18th, 2022
18 May 22
Daily Discussion Thread - May 17th, 2022
17 May 22
Daily Discussion Thread - May 16th, 2022
16 May 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
What Does It Mean When a Stock Behaves Like This? (ATRS)
18 Apr 22
Pre-Market Summary - April 14th
14 Apr 22
What Does This Mean When a Stock Behaves Like This? (ATRS)
13 Apr 22